Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.51
-0.4686-1.38%
Volume:3K
Turnover:102.86K
Market Cap:13.40M
PE:- -
High:33.77
Open:33.77
Low:33.14
Close:33.98
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:1.98
T/O Rate:0.76%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Yesterday

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Oct 07

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Oct 07

Early notable gainers among liquid option names on October 7th

TIPRANKS
·
Oct 07

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Oct 07

Edwards Lifesciences Price Target Announced at $110.00/Share by Barclays

Dow Jones
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Oct 07

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Oct 07

AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?

TIPRANKS
·
Oct 07

J.P. Morgan Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
Oct 07

Changchun High-Tech's Subsidiary Receives Approval for GenSci155 Injection Clinical Trial Application

Stock News
·
Oct 07

Beijing Centergate Subsidiary Wins Clinical Trial Approval for BDB Tablet

Stock News
·
Oct 07